Radiopharm Theranostics Limited

RAD

AU0000181851

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:44 2024-04-26 am EDT			5-day change	1st Jan Change
0.046 ^AUD	+2.22%		+2.22%	-37.84%

Feb. 29	Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study	MT
Feb. 29	Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023

February 28, 2024 at 10:43 pm EST

Radiopharm Theranostics Limited reported earnings results for the half year ended December 31, 2023. For the half year, the company reported net loss was AUD 24.76 million compared to AUD 12.55 million a year ago. Basic loss per share from continuing operations was AUD 0.0721 compared to AUD 0.0454 a year ago.

Latest news about Radiopharm Theranostics Limited

Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study	Feb. 29	MT
Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Radiopharm Theranostics Receives AU$1.9 Million Advance on R&D Tax Rebate	Feb. 20	MT
Radiopharm Secures Investment from US-based Lind Partners; Shares Decline 6%	Feb. 06	MT
Radiopharm Theranostics Raises AU$1.7 Million Via Shortfall Placement	Jan. 23	MT
Radiopharm Theranostics Secures Ethics Approval for Second Lung Cancer Trial Site	Dec. 26	MT
Radiopharm Theranostics to Start Phase One Lung Cancer Therapy Trial	Dec. 25	MT
Radiopharm Theranostics Raises AU$2.1 Million Via Entitlement Offer	Dec. 08	MT
28,046,696 Options of Radiopharm Theranostics Limited are subject to a Lock-Up Agreement Ending on 25-NOV-2023.	Nov. 24	CI
100,000,000 Ordinary Shares of Radiopharm Theranostics Limited are subject to a Lock-Up Agreement Ending on 25-NOV-2023.	Nov. 24	CI
Radiopharm Theranostics Secures AU$5 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 4%	Nov. 20	MT
Radiopharm Theranostics Secures US FDA Approval for Phase 1 Pancreatic Cancer Diagnostic Trial	23-10-17	MT
Radiopharm Theranostics Secures Ethics Approval for Lung Cancer Trial; Shares Rise 4%	23-10-08	MT
Radiopharm Theranostics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Radiopharm Theranostics Secures US FDA Guidance for Clinical Trial of Imaging Drug in Brain Metastasis	23-05-29	MT
Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer	23-05-09	CI
Radiopharm Theranostics Receives US FDA Orphan Drug Designation for Pancreatic Cancer Medication	23-05-09	MT
Radiopharm Theranostics Receives AU$1.6 Million R&D Tax Refund; Shares Fall 3%	23-03-27	MT
Radiopharm Theranostics, GenesisCare Partner to Develop Novel Radiopharmaceuticals in Australia	23-03-26	MT
Radiopharm Theranostics Limited and GenesisCare to Develop Novel Radiopharmaceuticals	23-03-26	CI
Radiopharm Theranostics Appoints Dr. Ken Herrmann to the Scientific Advisory Board	23-03-03	CI
Radiopharm Theranostics Acquiring Pharma15 for AU$6 Million	23-03-03	MT
Radiopharm Theranostics Limited entered into a binding agreement to acquire Pharma15 Corporation.	23-03-02	CI
Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-28	CI
Radiopharm Theranostics Starts NASDAQ Listing Process	23-02-14	MT

Chart Radiopharm Theranostics Limited

Duration

Period

More charts

Company Profile

Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company. The Company is focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The Company has a pipeline of six platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including breast, kidney and brain. The Company's technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, DUNP19 and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labeled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate that utilizes the early steps of fatty acid oxidation.

Sector

Pharmaceuticals

Calendar

2024-09-25 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.03 USD

Average target price

0.317 USD

Spread / Average Target

+956.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
RADIOPHARM THERANOSTICS LIMITED	-37.84%	13.55M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals